AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (currently amended) A device for implantation in the vasculature, comprising:

an elongate intraluminal element implantable in a portion of a vascular lumen, in which the vascular wall has undergone angioplasty restoring the lumen, said elongate intraluminal element occupying a volume of said vascular lumen in said portion without reducing the blood flow through said vascular lumen and without exerting appreciable mechanical action on a vascular wall, said element being associated with a means of fixing into the vascular lumen, said device being made of a biodegradable material, whereby said device can be naturally eliminated in the blood flow.

2. (canceled)

3. (original) The device as claimed in claim 1 having a proximal end or anchoring zone (12, 13, 18, 19, 23, 31) that can be fixed to or through the wall of the vessel, followed by a rod and by a distal end which is free in the blood stream so that only the anchoring zone is in permanent contact with the tissues of the vessel.

4. (original) The device as claimed in claim 1, with a diameter of 0.5 to 2 mm and a length of 0.5 to 15 cm.

5. (original) The device as claimed in claim 1, with a cross section of between 5 and 50% of the cross section of the vessel in which it is implanted.

6. (original) The device as claimed in claim 1, with a cross section of between 10 and 20% of the cross section of the vessel in which it is implanted.

7. (currently amended) The device as claimed in ~~one of claims~~ claim 1, in which said fixing means comprises an anchoring zone made of a material which, when the device is placed in the vascular lumen, allows a change in shape leading to at least two points of contact with the vascular wall.

8. (original) The device as claimed in claim 1, in which said fixing means (23, 31) comprises an anchoring zone allowing direct implantation in the wall of the vessel.

9. (original) The device as claimed in claim 8, characterized in that said anchoring zone is made of a material allowing it to deform when the device is placed in the vascular lumen.

10. (original) The device as claimed in claim 7, characterized in that it is deformable into a roughly straight position so that it can be fitted using a needle or a catheter.

11. (currently amended) The device as claimed in claim [[1]] 24, in which said fixing means are arranged to allow said device to be withdrawn.

12. (currently amended) The device as claimed in claim [[1]] 24, made of stainless steel, alloy or plastic.

13. (currently amended) The device as claimed in claim [[1]] 24, made of nylon, polysulfone, of Teflon or of silicone.

14. (canceled)

15. (currently amended) The device as claimed in claim [[1]] 24, the surface of which is covered with a coating.

16. (original) The device as claimed in claim 15, in which said coating is made of hyaluronic acid, collagen, PEG, glycol, hydrogel or PLGA.

17. (original) The device as claimed in claim 1, containing a releaseable active principle.

18. (original) The device as claimed in claim 17 in which the active principle is Lanreotide, hydrocortisone, a glucocorticoid or a cytostatic.

19. (original) The device as claimed in claim 12, the surface of which is hydrophilic, silicone coated or surfaced.

20. (original) The device as claimed in claim 1, produced by melt extrusion or co-extrusion or by die-forming and drawing.

21. (new) A device as claimed in claim 1, wherein said biodegradable material is PLGA.

22. (new) The device of claim 21, containing a releasable active principle.

23. (new) The device of claim 22 in which the active principle is Lanreotide.

24. (new) A device for implantation in the vasculature, comprising:

an elongate intraluminal element implantable in a portion of a vascular lumen, in which the vascular wall has undergone angioplasty restoring the lumen, said elongate intraluminal element occupying a volume of said vascular lumen in said portion without reducing the blood flow through said vascular lumen and without exerting appreciable mechanical action on the vascular wall, said element being associated with a means of fixing into the vascular lumen, wherein said device contains a releasable active principle capable of avoiding or reducing the risk of restenosis.

25. (new) The device as claimed in claim 24, in which the active principle is Lanreotide, hydrocortisone, a glucocorticoid or a cytostatic.

26. (new) The device as claimed in claim 25 in which the active principle is Lanreotide.

27. (new) The device as claimed in claim 24 having a proximal end or anchoring zone (12, 13, 18, 19, 23, 31) that can be fixed to or through the wall of the vessel, followed by a rod and by a distal end which is free in the blood stream so that only the anchoring zone is in permanent contact with the tissues of the vessel.

28. (new) The device as claimed in claim 24, with a diameter of 0.5 to 2 mm and a length of 0.5 to 15 cm.

29. (new) The device as claimed in claim 24, with a cross section of between 5 and 50% of the cross section of the vessel in which it is implanted.

30. (new) The device as claimed in claim 24, with a cross section of between 10 and 20% of the cross section of the vessel in which it is implanted.

31. (new) The device as claimed in claim 24, in which said fixing means comprises an anchoring zone made of a material which, when the device is placed in the vascular lumen, allows a change in shape leading to at least two points of contact with the vascular wall.

32. (new) The device as claimed in claim 24, in which said fixing means (23, 31) comprises an anchoring zone allowing direct implantation in the wall of the vessel.

33. (new) The device as claimed in claim 24, characterized in that said anchoring zone is made of a material

allowing it to deform when the device is placed in the vascular lumen.

34. (new) The device as claimed in claim 31, characterized in that it is deformable into a roughly straight position so that it can be fitted using a needle or a catheter.

35. (new) The device of claim 15 in which said active principle is Lanreotide.

36. (new) The device of claim 16 in which said active principle is Lanreotide.

37. (new) The device of claim 36 in which said coating is made of PLGA.

38. (new) The device as claimed in claim 12, the surface of which is hydrophilic, silicone coated or surfaced.

REMARKS

Changes in the claims are made so as to present the claim schedule in what is believed to be the best form.

Please charge the fee of $288 for the 16 extra claims of any type added herewith, to Deposit Account No. 25-0120.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON



Robert J. Patch, Reg. No. 17,355
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297

RJP/lk